7200 Lake Ellenor Dr. Suite 252 Orlando, Florida 32809 USA



Phone: (407) 240-0085
Toll Free: (888) 416-1464
Fax: (407) 240-1007
info@patentinternational.com
www.patentinternational.com

FACSIMILE COVER SHEET

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

TO

Examiner Tina Kachevis

COMPANY

USPTO

FAX No.

703-746-5204

No of PAGES

(including cover sheet)
Van Dyke & Associates, P.A.

FROM DATE

September 29, 2003

RE

Terminal Disclaimer for Docket AdVec101A-C2;

Application Ser. No.: 09/981,648, & attachments.

SENT BY FACSIMILE ONLY

Dear Examiner Kachevis:

Based on our conversation this morning, I attach for entry into the abovereferenced application the following documents:

- 1) PTO Form SB-26 Terminal Disclaimer (1 page);
- 2) PTO Form SB-96 Statement Under CFR3.73(b)(1 page);
- 3) Relevant Assignment (4 pages); and
- 4) PTO Form 2038 for payment of Disclaimer Fees in the amount of \$110.

Thank you,

Joseph Fischer, Reg'n. No.: 51,210, Associate

Van Dyke & Associates, P.A.

If you do not receive all pages or if any portion of this transmission is not legible, call the sender at (407) 240-0085.

P10/S8/26 (08-03) Approved for use through 07/31/2006, OMB 0651-0031

SEP-29-03 3:33PM:

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number (Optional) TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT In re Application of: Graham et al. Application No.: 09/981,648 10/16/2001 Filed: Enhanced System for Construction of Adenovirus Vectors For: __percent interest in the instant application hereby The owner*, Merck & Co., Incof 100 disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of record. Telephone Number Terminal disclaimer fee under 37 CFR 1,20(d) included. WARNING: Information on this form may become public, Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement_under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 millious to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patont and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SENT BY: VAN DYKE LAW;

-- ----,

PTO/SB/96 (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMS control number STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: Merck & Co., Inc. Application No./Patent No.: 09/981,648 Filed/Issue Date: 10/16/2001 Entitled: Enhanced System for Construction of Adenovirus Vectors Merck & Co., Inc. <u>corporation</u> (Typa of Assignee, e.g., corporation, partnership, university, government agency, etc.) (Name of Assignee) states that it is: 1. M the assignee of the entire right, title, and interest; or an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is -in the patent application/patent identified above by virtue of either: A, [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel ______, Frame _____, or for which a copy thereof is attached. OR B. M A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown All inventors, Graham, To: Merck & Co., Inc. Parko & Ng 1. From: --The document was recorded in the United States Patent and Trademark Office at ____, or for which a copy thereof is attached. , Frame The document was recorded in the United States Patent and Trademark Office at , or for which a copy thereof is attached. Reel _____, Frame 3. From: The document was recorded in the United States Patent and Trademark Office at __, Frame __ _, or for which a copy thereof is attached. [] Additional documents in the chain of title are listed on a supplemental sheet. [V] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. 407-240-0085 Telephone number

This collection of Information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time your require to complete this form and/or suggestions reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Title

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SENT BY: VAN DYKE LAW;

Attorney Docket No. ADVEC-10IA

ASSIGNMENT OF PATENT APPLICATION

FOR GOOD AND VALUABLE CONSIDERATION,

We, the undersigned (each) have agreed and hereby agree to assign for good and valuable consideration, receipt of which is hereby expressly acknowledged, and do hereby sell, assign and transfer unto

Merck & Co., Inc.

a corporation organized under the laws of the state of New Jersey as Assignee, and its successors, assigns and legal representatives, the entire right, title and interest owned by the undersigned, for all countries in and to certain inventions relating to

Enhanced System for Construction of Adenovirus Vectors

described in an application for Letters Patent of the United States, identified as Attorney Docket No. ADVEC-10IA, at Van Dyke & Associates, P.A., 7200 Lake Effenor Drive, Suite 252, Orlando, FL 32809 and filed on 10/8/1999, as Application Serial No. 09/415,899, and the invention(s) and improvement(s) set forth therein, and any and all continuations, continuations-in-part, divisionals, and renewals of and substitutes for said application for said Letters Patent, and all the rights and privileges under any and all Letters Patent that may be granted therefor in any country, and any reissues, or reexaminations, or extensions of said Letters Patent. We request that any and all Letters Patent for said inventions be issued to said Assignee, its successors, assigns and legal representatives, or to such nominees as it may designate.

We agree that, when requested, we will, without charge to said Assignee but at its expense, sign all papers, take all rightful oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said inventions in any and all countries and for vesting title thereto in said Assignee, its successors, assigns and legal representatives or nominees.

We authorize and empower the said Assignee, its successors, assigns and legal representatives or nominees, to invoke and claim for any application for patent or other form of protection for said inventions filed by it or them, the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as

amended, or by any convention which may henceforth be substituted for it, and to invoke and claim such right of priority without further written or oral authorization from us.

We hereby consent that a copy of this assignment shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be required in any country for any purpose and more particularly in proof of the right of the said Assignee or nominee to claim the aforesaid benefit of the right of priority provided by the International convention which may henceforth be substituted for it.

We covenant with said Assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that we have full right to convey the same as herein expressed.

IN WITNESS WHEREOF, we have hereunto signed our names on the day and year set forth below.

Inventor's Signature DATE

Frank L. Graham
Inventor's Printed Name

On this the above named Frank L. Graham who is personally known by me or proved to me on the basis of satisfactory evidence to be the same individual who executed the foregoing assignment, and who acknowledged to me that he/she executed the same of his/her own free will for the use and purposes therein set forth.

NOTARY PUBLIC

My Commission Expires: _____

City/Province

Country

Page 2 of 4

Inventor	's Signatu) _{eo}	 <u>.</u>	Dec C	?(9 00 8	· · · · · · · · · · · · · · · · · · ·				
Robin	Parks .									-
	's Printed	Name	,							
	,		-							•
			a.							•
On this _	9-	lay of	Decew	uber		. 2002.1	before	me per	riknos	came
assignme	satistacto int, and w	ho acknot	ce to be vledged to	the sam me tha	ally kno ic indivi it he/she ith.	dual wh	o exe	cuted t	he fore, f his/her	going own
assignme	satistacto int, and w	ry eviden ho acknov and purp	ce to be vledged to	the sam me tha	ic indivi it he/she	dual wh	o exe	cuted t	he fore	going own
assignme	satistacto int, and w	ho acknot	ce to be vledged to	the sam me tha	ic indivi it he/she	dual wh	o exe	cuted t	he fore, f his/her	going own
assignme	satistacto int, and w	ho acknot	ce to be vledged to	the sam me tha	ic indivi it he/she	dual wh	o exe	same of	f his/her	own ≤
assignme	satistacto int, and w	ho acknot	ce to be vledged to	the sam me tha	ic indivi it he/she	dual wheexecute	o exe	same of	f his/her	going own = x 6, 2005
assignme	satistacto int, and w	ho acknot	ce to be vledged to	the sam me tha	ic individual he/she with.	dual wheexecute	o exe	same of	f his/her	own ≤

,	philip	3		Dec	5/02	3.		٠
Inventor	's Signatu	A	D	ATE	/			
Philip N Inventor	lg 's Printed	Name	·		٠.			
of satisfa and who	e named I octory evic acknowle	lence to be	the same i that he/s	onally kno ndividual	wn by me	or proved	to me on the going assign own free w	basis
					NOTARY My Comm	PUBLIC nission Exp	Je Carre ires: 2/2/0/	<u>1</u> 05
					Hous City/Provi	ton, T	TENES	<u>-</u>
					Country	WALL SOLD	MANAGER PORTS	

PTO-2038 (02-2000)

Approved for use through 01/31/2003. OMB 0651-0043 United States Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays valid OMB control number.

United States Patent & Trademark Office

Credit Card Payment Form Please Read Instructions before Completing this Form

Credit Card Information							
Credit Card Type:	X Visa	Master Ca	ard	American Exp	ress	Discover	
Credit Card Account #: 4223 0712 0901 1547							
Credit Card Expiration Dat		:					
Name as it Appears on Cre	edit Card: Timo	thy H. Van D	yke			:	
Payment Amount: \$(US D	ollars): \$110.00						
Signature:	Ja 1/2			Date: Septem	ber 29, 2003		
Refund Policy: The Office may a fee will not entitle a party to a specifically requested, and will no credit to the credit card account Service Charge: There is a 50,00 back by a financial institution (37 CF)	refund of such fee. of notify the payor of service charge for p R 1,21(m)). Cred	The Office will red such amounts rocessing each p	iot refund ai (37 CFR 1.2 ayment refu	mounts of twenty-fiven	re dollars or less to paid by credit ca	inless a refund is ind will be via	
Street Address 1: 7200 La		/e					
Street Address 2: Suite 2:	52						
City: Orlando				, , , , , , , , , , , , , , , , , , , 			
State: Florida Zip/F					p/Postal Code: 32809		
Country: USA							
Daytime Phone #: 407-240-0085				Fax #: 407-24			
Description of Request and P	Request ayment Information	and Payr	nent In Disclaimer	formation Fee 37 CFR 1.20	(d)		
Patent Fee	Patent Mainte	enance Fee	Tra	demark Fee	Other Fee		
Application No. 09/981,648	Application No.		Serial No.		IDON Customer	IDON Customer No.	
Patent No.	Patent No.		Registration No.				
Attorney Docket No Adv c10IA-C2			Identify or Describe Mark			·	

If the cardholder includes a credit card number on any form or document other than the Credit Card Payment Form, the United States Patent & Trademark Office will not be liable in the event that the credit card number becomes public knowledge.